Clinical Trial Update: Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis [Phase 1, Phase 2]

View source ↗

Summary

Proof-of-concept Phase 1/2 study of AX-158 in patients with mild to moderate plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• AX-158

Snippet

Sponsor: Artax Biopharma Inc | Conditions: Psoriasis, Plaque Psoriasis | Phase 1, Phase 2 | Status: COMPLETED